Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
P/E ratio for Athira Pharma, Inc. (ATHA)
P/E ratio as of 2023: -0.79
According to Athira Pharma, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.79. At the end of 2022 the company had a P/E ratio of -1.37.
P/E ratio history for Athira Pharma, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.79 |
| 2022 | -1.37 |
| 2021 | -8.85 |
| 2020 | -59.71 |
| 2019 | -118.70 |
| 2018 | -20.77 |